Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

Carna receives CTA clearance for phase I study of BTK inhibitor AS-1763

March 2, 2021

FDA issues complete response letter for oral paclitaxel plus encequidar in metastatic breast cancer

March 2, 2021

Myoferlin inhibitor YQ-456 shows efficacy in PDX model of colorectal cancer

March 2, 2021

Alofanib shows safety and antitumor efficacy in patients with advanced gastric cancer

March 2, 2021

Amgen discovers kinesin-like protein KIF18A inhibitors

March 2, 2021

Bristol Myers Squibb presents new ROR-gammaT agonists

March 2, 2021

VBL Therapeutics initiates dosing patients in phase II study of VB-111 in rGBM

March 2, 2021

Oncorena cleared to begin phase I/II study in Sweden with orellanine for metastatic renal cancer

March 1, 2021

FDA grants accelerated approval to Pepaxto for relapsed or refractory melanoma

March 1, 2021

Pilot trial investigates magnetic nanoparticles to treat locally advanced pancreatic cancer

March 1, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...